Niacin ERThird Party Manufacturing in India

Niacin ER works by modulating lipid metabolism in the liver and adipose tissue.

It inhibits diacylglycerol acyltransferase-2, a key enzyme involved in triglyceride synthesis, leading to decreased production of VLDL and LDL cholesterol. Additionally, it increases the half-life of apolipoprotein A-I, which elevates HDL (good cholesterol) levels.

Unlike other lipid-lowering agents, Niacin has a unique ability to significantly raise HDL while simultaneously lowering triglycerides and LDL. The extended-release formulation minimizes flushing, a common side effect.

Therapeutic Uses

Niacin ER is prescribed for the treatment of:

• Dyslipidemia: To reduce elevated total cholesterol, LDL-C, and triglycerides, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia.
• Cardiovascular Disease: Used as an adjunct therapy to reduce the risk of recurrent myocardial infarction in patients with a history of heart disease.

Why Manufacturers Choose Niacin ER

The extended-release formulation of Niacin provides improved patient tolerability compared to immediate-release versions, driving sustained market demand. Its dual action on both LDL and HDL makes it a versatile cardiovascular drug.

This makes Niacin ER one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and cardiac specialists.